Stay updated on Ruxolitinib vs BAT in Chronic GvHD Clinical Trial

Sign up to get notified when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The site footer revision identifier changed from v3.8.0 to v3.8.1.
    Difference
    0.0%
    Check dated 2026-11-19T11:43:35.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The clinical trial record for the REACH3 study is displayed, including its study design, eligibility criteria, treatment arms, outcomes, locations, publications, and study documents.
    Difference
    100%
    Check dated 2026-11-12T11:07:46.000Z thumbnail image
  3. Check
    14 days ago
    No Change Detected
  4. Check
    21 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-29T11:13:05.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    A site-wide NIH notice was added, announcing a website transition and stating that some NIH content will use “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-22T09:59:40.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The error page footer now displays revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-15T12:33:35.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.0 to v3.7.1. The study page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-08T13:12:38.000Z thumbnail image

Stay in the know with updates to Ruxolitinib vs BAT in Chronic GvHD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.